Zscaler forecasts 16%-17% fiscal 2027 ARR and revenue growth while targeting $4.10-$4.11 FY2026 EPS (NASDAQ:ZS)May 27, 2026
Share Facebook Twitter LinkedIn Pinterest Email Connect and Simcere sign license agreement for autoimmune drug Rademikibart
Zscaler forecasts 16%-17% fiscal 2027 ARR and revenue growth while targeting $4.10-$4.11 FY2026 EPS (NASDAQ:ZS)May 27, 2026